Teva Pharmaceutical Industries Ltd (TA:TEVA) — Market Cap & Net Worth
Market Cap & Net Worth: Teva Pharmaceutical Industries Ltd (TEVA)
Teva Pharmaceutical Industries Ltd (TA:TEVA) has a market capitalization of $1.09 Billion (ILA406.17 Billion) as of May 7, 2026. Listed on the TA stock exchange, this Israel-based company holds position #8746 globally and #88 in its home market, demonstrating a 10.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Teva Pharmaceutical Industries Ltd's stock price ILA10360.00 by its total outstanding shares 1164403205 (1.16 Billion). Analyse Teva Pharmaceutical Industries Ltd cash conversion from operations to see how efficiently the company converts income to cash.
Teva Pharmaceutical Industries Ltd Market Cap History: 2015 to 2026
Teva Pharmaceutical Industries Ltd's market capitalization history from 2015 to 2026. Data shows change from $78.15 Billion to $32.34 Billion (-7.25% CAGR).
Teva Pharmaceutical Industries Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Teva Pharmaceutical Industries Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.69x
Teva Pharmaceutical Industries Ltd's market cap is 1.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
20.62x
Teva Pharmaceutical Industries Ltd's market cap is 20.62 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $42.78 Billion | $21.90 Billion | $329.00 Million | 1.95x | 130.03x |
| 2017 | $20.31 Billion | $22.39 Billion | -$16.27 Billion | 0.91x | N/A |
| 2018 | $18.31 Billion | $18.85 Billion | -$2.15 Billion | 0.97x | N/A |
| 2019 | $10.68 Billion | $16.89 Billion | -$999.00 Million | 0.63x | N/A |
| 2020 | $9.54 Billion | $16.66 Billion | -$3.99 Billion | 0.57x | N/A |
| 2021 | $8.41 Billion | $15.88 Billion | $417.00 Million | 0.53x | 20.18x |
| 2022 | $10.30 Billion | $14.93 Billion | -$2.35 Billion | 0.69x | N/A |
| 2023 | $11.91 Billion | $15.85 Billion | -$559.00 Million | 0.75x | N/A |
| 2024 | $25.29 Billion | $16.54 Billion | -$1.64 Billion | 1.53x | N/A |
| 2025 | $31.50 Billion | $18.68 Billion | $1.53 Billion | 1.69x | 20.62x |
Competitor Companies of TEVA by Market Capitalization
Companies near Teva Pharmaceutical Industries Ltd in the global market cap rankings as of May 7, 2026.
Key companies related to Teva Pharmaceutical Industries Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #498 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #524 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #534 globally with a market cap of $49.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #573 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #498 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #524 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #534 | Zoetis Inc | NYSE:ZTS | $49.60 Billion | $112.54 |
| #573 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.24 |
Teva Pharmaceutical Industries Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Teva Pharmaceutical Industries Ltd's market cap moved from $78.15 Billion to $ 32.34 Billion, with a yearly change of -7.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA32.34 Billion | +2.68% |
| 2025 | ILA31.50 Billion | +24.55% |
| 2024 | ILA25.29 Billion | +112.35% |
| 2023 | ILA11.91 Billion | +15.64% |
| 2022 | ILA10.30 Billion | +22.41% |
| 2021 | ILA8.41 Billion | -11.78% |
| 2020 | ILA9.54 Billion | -10.70% |
| 2019 | ILA10.68 Billion | -41.67% |
| 2018 | ILA18.31 Billion | -9.87% |
| 2017 | ILA20.31 Billion | -52.52% |
| 2016 | ILA42.78 Billion | -45.26% |
| 2015 | ILA78.15 Billion | -- |
End of Day Market Cap According to Different Sources
On May 6th, 2026 the market cap of Teva Pharmaceutical Industries Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.09 Billion USD |
| MoneyControl | $1.09 Billion USD |
| MarketWatch | $1.09 Billion USD |
| marketcap.company | $1.09 Billion USD |
| Reuters | $1.09 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more